Dosing underway in third cohort of OPTIC trial of ADVM-022

The first patient has been dosed in the third cohort of the OPTIC phase 1 clinical trial of ADVM-022, an intravitreal gene therapy for the treatment of wet age-related macular degeneration, according to a press release from Adverum Biotechnologies.

Patients in this cohort are receiving a single injection of ADVM-022 at a dose of 2 × 1011 vg per eye.

“This expansion of OPTIC will generate important clinical data to support the further development of ADVM-022,” Aaron Osborne, MBBS, chief medical officer of Adverum, said in the release. “Based on the recently presented data from the first cohort of OPTIC, which demonstrated a sustained response to a single injection of ADVM-022 out to a median of 34 weeks, with no patient in the first cohort requiring anti-VEGF rescue therapy, we believe that ADVM-022 has the potential to be a transformative treatment option for patients with wet AMD.”

The multicenter, open-label trial is assessing the safety and tolerability of ADVM-022, which uses a proprietary vector capsid carrying an aflibercept coding sequence and is designed to reduce the burden of frequent anti-VEGF injections.

The first patient has been dosed in the third cohort of the OPTIC phase 1 clinical trial of ADVM-022, an intravitreal gene therapy for the treatment of wet age-related macular degeneration, according to a press release from Adverum Biotechnologies.

Patients in this cohort are receiving a single injection of ADVM-022 at a dose of 2 × 1011 vg per eye.

“This expansion of OPTIC will generate important clinical data to support the further development of ADVM-022,” Aaron Osborne, MBBS, chief medical officer of Adverum, said in the release. “Based on the recently presented data from the first cohort of OPTIC, which demonstrated a sustained response to a single injection of ADVM-022 out to a median of 34 weeks, with no patient in the first cohort requiring anti-VEGF rescue therapy, we believe that ADVM-022 has the potential to be a transformative treatment option for patients with wet AMD.”

The multicenter, open-label trial is assessing the safety and tolerability of ADVM-022, which uses a proprietary vector capsid carrying an aflibercept coding sequence and is designed to reduce the burden of frequent anti-VEGF injections.